Research & Development

We focus on regenerative medicine and protein supplemental therapy, which are critical to improve patient’s quality of life. We pursue safe and secure treatments utilize our proprietary technology of transduction of pre-adipocytes, especially for intractable diseases and orphan diseases.


Protein supplemental therapy by transduced pre-adipocytes

Our platform technology is based on autotransplantation of transduced pre-adipocytes which produce therapeutic proteins. The applications can be various in a wide range of diseases. Current lead pipeline targets reverse cholesterol transport enzyme in congenital metabolic disorder, which is in preclinical.
More programs including Factor VIII for Hemophilia A and Diabetes are on-going.

Skin ulcer treatments by stem cell mobilization

External application of a chemokine for intractable and refractory skin ulcers such as bedsores and leg ulcers is being examined. Another preliminary trial of a protein drug candidate is also planned as a back-up product.